Présentation de l'entreprise
Co-Diagnostics, Inc. operates within the healthcare sector, specifically focusing on the medical devices industry, where it develops, manufactures, and sells reagents designed for diagnostic tests that detect and analyze nucleic acid molecules. The firm's core business revolves around the Co-Dx PCR platform, which is utilized for diagnostic purposes in both the United States and international markets. As a mid-sized entity in this specialized niche, the company currently employs 115 individuals to support its manufacturing and sales operations. With a market capitalization of $5.01M and annual revenue of $622,489, the company presents a small-cap profile typical of early-stage medical technology firms. These valuation metrics suggest a position where the market places a significant premium on future growth potential rather than current profitability, indicating that the company is valued primarily on its proprietary technology and expansion capabilities rather than established cash flow generation.
Santé financière
The company reported a trailing twelve-month revenue of $622,489, yet it recorded a net income of $-46,895,936 and an EBITDA of $-30,176,544, revealing a substantial disparity between top-line sales and bottom-line profitability. This significant gap between revenue and net income indicates a highly leveraged cost structure where expenses, likely including R&D, regulatory compliance, or restructuring costs, are far outpacing the modest revenue stream. The free cash flow stands at $-19,684,820, which signals that the company is currently burning cash rather than generating liquidity, thereby limiting its immediate financial flexibility and necessitating external funding to sustain operations. Margin analysis further highlights financial distress, with a gross margin of 64.3% that suggests efficient production costs relative to sales, contrasted sharply by an operating margin of -2902.3% and a profit margin of 0.0% that reflect severe operational inefficiencies or one-time losses. On the liability side, the company holds $11.88M in cash against $1.24M in debt, resulting in a debt-to-equity ratio of 5.99, which classifies the balance sheet as aggressively leveraged despite the apparent cash cushion. Liquidity is currently strong with a current ratio of 3.87, indicating sufficient short-term assets to cover short-term obligations, although this does not mitigate the underlying profitability issues. Return on equity is reported at -125.9% and return on assets at -44.3%, metrics that reveal that management has been ineffective at generating value for shareholders or utilizing assets to produce profit, a common characteristic of pre-revenue or loss-making biotech ventures.
Évaluation de la valorisation
Valuation metrics for Co-Diagnostics present a complex picture due to the lack of consistent profitability. The trailing P/E ratio is N/A, while the forward P/E is -0.12, implying that the market is pricing the stock based on future earnings expectations that are currently negative, rather than historical performance. The price-to-book ratio of 0.14 indicates that the market values the company at a significant discount to its book value, suggesting that investors are skeptical of the quality of its intangible assets or future earnings potential. Alternative valuation metrics such as the price-to-sales ratio of 8.04 and an EV/EBITDA of 0.19 provide additional context, showing that the stock is trading at a high multiple relative to its sales despite negligible earnings power. The 52-week price range spans from a low of $1.38 to a high of $46.50, meaning the current price sits significantly below the recent 52-week high, reflecting the recent volatility and potential correction in the stock's trajectory. The stock exhibits a beta of 1.43, which means its price volatility is 43% higher than that of the broader market, indicating that the shares are highly sensitive to general market movements and sector-specific sentiment.
Growth & Income
The company demonstrates robust top-line expansion with a year-over-year revenue growth of 76.7%, while earnings growth is N/A due to the continued negative net income. This divergence implies that the company is prioritizing revenue expansion and market penetration over immediate profitability, a strategy typical of companies in the development phase of their product lifecycle. Regarding income distributions, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the company does not pay dividends and instead retains all available capital to fund operations and research. This reinvestment approach is necessary given the negative net income, as the company must conserve cash reserves to cover its substantial operating losses and debt obligations. The overall growth and income profile is characterized by high revenue acceleration but a complete absence of shareholder returns or earnings stability, positioning the stock as a speculative vehicle rather than an income-generating asset.